Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 2, 2014, Pages

  Smyth, Alan R ^a   Bhatt, Jayesh ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CEFTAZIDIME; TOBRAMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

BODY MASS; BODY WEIGHT GAIN; CREATININE CLEARANCE; CYSTIC FIBROSIS; DATA BASE; DRUG EFFICACY; DRUG SAFETY; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; NEPHROTOXICITY; NUTRITIONAL STATUS; OTOTOXICITY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; ADOLESCENT; ADULT; BACTERIAL INFECTION; CHILD; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LUNG DISEASE; MALE; META ANALYSIS; METHODOLOGY; MICROBIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADOLESCENT; ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CHILD; CYSTIC FIBROSIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LUNG DISEASES; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84907629386     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD002009.pub5     Document Type: Review

References (59)

1. Riethmueller J, Ballmann M, Schroeter TW, Franke P, von Butler R, Claass A, et al.Tobramycin once-vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection 2009;37(5):424-31. [CFGD Register: PI154f]
2. Riethmueller J, Busch A, Franke P, Ziebach R, von Butler R, Stern M. Pharmacodynamic variation of intravenous antibiotic treatment with ceftazidime and tobramycin in CF-patients is equally effective [abstract]. 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden. 2000:166.
3. Riethmueller J, Franke P, Schroeter TW, Claass A, Busch A, Ziebach R, et al.Optimized intravenous antibiotic treatment with ceftazidime (thrice-daily vs. continuous) and tobramycin (thrice vs. once-daily) in CF patients [abstract]. Abstracts of the 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P192.
4. Riethmueller J, Junge S, Schroeter TW, Kuemmerer K, Franke P, Ballmann M, et al.Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection 2009;37(5):418-23. [CFGD Register: PI154e]
5. Schroeter T, Eggert P, Riethmueller J, Stern M, Claass A. Acute-phase nephrotoxicity of tobramycin in CF patients: a prospective randomized trial of once-versus thrice-daily dosing. Pediatric Pulmonology 2002;34(Suppl 24):289.
6. Schroeter TW, Eggert P, Riethmueller J, Stern M, Claass A. A prospective randomized trial on the nephrotoxicity of thrice-daily versus once-daily tobramycin in cystic fibrosis patients [abstract]. Abstracts of the 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna, Austria. 2001:P190.
7. Mulheran M, Hyman-Taylor P, Tan KH, Lewis S, Stableforth D, Knox A, et al.Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once-versus three-times-daily tobramycin in cystic fibrosis patients. Antimicrobial Agents and Chemotherapy 2006;50(7):2293-9.
8. Smyth A, Docherty C, Govan J, Tan K, Hyman-Taylor P, Stableforth D, et al.Once daily tobramycin achieves cidal levels against Pseudomonas aeruginosa in patients with cystic fibrosis [abstract]. Thorax 2001;56(Suppl 3):iii84.
9. Smyth A, Tan K H-V, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, et al.Once vs. three times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis -the TOPIC study: a randomised controlled trial. Lancet 2005;365(9459):573-8.
10. Smyth A, Tan K, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, et al.A randomised controlled trial of once vs three times daily tobramycin for pulmonary exacerbations of cystic fibrosis [abstract]. Pediatric Pulmonology. 2003, issue Suppl 25:292.
11. Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics (PK) of tobramycin administered thrice daily (TD) and once daily (OD) in children and adults with CF [abstract]. Journal of Cystic Fibrosis 2007;6(Suppl 1):S16.
12. Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. Journal of Cystic Fibrosis 2007;6(5):327-33.
13. VandenBussche HL, Klepser ME. Single daily tobramycin dosing in cystic fibrosis: is it better for the patients or the bugs [comment]. Lancet 2005;365:547-8.
14. Canis F, Trivier D, Vic P, Ategbo S, Turck D, Husson MO. Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in three doses in cystic fibrosis [Comparaison de la pharmacocinetique de la tobramycine administree en dose unique journaliere ou en trois doses dans la mucoviscidose]. Pathologie-biologie 1998;46(6):449-51.
15. Vic P, Ategbo S, Turck D, Husson MO, Launay V, Loeuille GA, et al.Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Archives of Disease in Childhood 1998;78(6):536-9.
16. Vic P, Ategbo S, Turck D, Husson MO, Launay V, Loueille GA, et al.Efficacy, tolerance and pharmokinetics of once-daily (OD) versus thrice-daily (TD) Tobramycine (TBM) for Pseudomonas aeruginosa (PA) pulmonary exacerbations [abstract]. Pediatric Pulmonology 1996;22(Suppl 13):293.
17. Watson A, Whitehead A, Conway SP, Etherington C. Efficacy and safety of once daily tobramycin in treating acute respiratory exacerbations in adult patients [abstract]. Pediatric Pulmonology 1999;28(Suppl 19):262-3.
18. Whitehead A, Conway SP, Etherington C, Caldwell NA, Setchfield N, Bogle S. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. European Respiratory Journal 2002;19(2):303-9.
19. Whitehead A, Conway SP, Etherington C, Dave J. Efficacy and safety of once daily tobramycin in treating acute respiratory exacerbations in adult patients [abstract]. The Netherlands Journal of Medicine 1999;54(Suppl):S36-37.
20. Adeboyeku D, Jones AL, Hodson ME. Twice vs three-times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. Journal of Cystic Fibrosis 2011;10(1):25-30. [CFGD Register: PI243]
21. Aminimanizani A, Beringer PM, Kang J, Tsang L, Jelliffe RW, Shapiro BJ. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy 2002;50(4):553-9.
22. Tsang L, Aminimanizani A, Beringer PM, Jelliffe R, Shapiro B. Pharmacokinetics of once-daily tobramycin in adult cystic fibrosis patients [abstract]. Pediatric Pulmonology 2000;30(Suppl 20):284.
23. Burkhardt O, Lehmann C, Madabushi R, Kumar V, Derendorf H, Welte T. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?. Journal of Antimicrobial Chemotherapy 2006;58(4):822-9.
24. Hamner JR, Poppy A, Ebaugh S, Reiter PD, Pan Z, Wagener J, Sagel S. Pharmacokinetics and safety of once-daily tobramycin in children with cystic fibrosis. Pediatric Pulmonology 2006;41(S29):326.
25. Heininger U, Bowing B, Stehr K, Solbach W. Aminoglycosides in patients with mucoviscidosis and pulmonary exacerbation. Comparison of once or three times daily administration [Aminoglykoside bei Patienten mit Mukoviszidose und pulmonaler Exazerbation: Vergleich von Einmal-und Dreimalgabe]. Klinische Padiatrie 1993;205(1):18-22.
26. Master V, Martin AJ, Holmes M, Roberts G, Coulthard K, Kennedy D, et al.Once daily tobramycin monotherapy versus conventional antibiotic therapy for the treatment of pseudomonal pulmonary exacerbations in cystic fibrosis patients [abstract]. European Respiratory Journal 1997;10(Suppl 25):162s.
27. Master V, Roberts GW, Coulthard KP, Baghurst PA, Martin A, Roberts ME, et al.Efficacy of Once-daily Tobramycin Monotherapy for Acute Pulmonary Exacerbations of Cystic Fibrosis: A Preliminary Study. Pediatric Pulmonology 2001;31(5):367-76.
28. Postnikov SS, Semykin SY, Polikarpova SV, Dubovik LG, Gracheva LA, Sagatelyan RM. A prospective trial on the efficacy and tolerability of twice-daily dosing (TDD) versus once-daily dosing (ODD) amikacin in cystic fibrosis patients [abstract]. Journal of Cystic Fibrosis 2007;6(Suppl 1):S34.
29. Powell SH, Stern RC, Thompson WL. Safety of once daily therapy with high-dose tobramycin [abstract]. 20th Annual Meeting Cystic Fibrosis Club Abstracts; 1979 May 1; Atlanta, Georgia. 1979.
30. Powell SH, Thompson WL, Luthe MA, Stern RC, Grossniklaus DA, Bloxham DD, et al.Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. Journal of Infectious Diseases 1983;147(5):918-32.
31. Winnie GB, Cooper JA, Witson J, Cowan RG, Mayer D, Lepow M. Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients. Pediatric Infectious Disease Journal 1991;10(5):381-6.
32. Wood PJ, Ioannides Demos LL, Li SC, Williams TJ, Hickey B, Spicer WJ, et al.Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax 1996;51(4):369-73.
33. Al Ansari NA, Foweraker J, Mackeown D, Bilton D. Evaluation of once daily tobramycin versus the traditional three times daily for the treatment of acute pulmonary exacerbations in adult cystic fibrosis patients [abstract]. Qatar Medical Journal 2006;15(1):34-8. [CFGD Register: PI173b; MEDLINE: 97294575]
34. Al Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, Walshaw MJ. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatric Pulmonology 2005;39(1):15-20.
35. Barza M, Ioannidis JPA, Cappelleri JC, Lau J. Single or multiple daily dosing of aminoglycosides: a meta-analysis. BMJ 1996;312(7027):338-45.
36. Bertenshaw C, Watson AR, Lewis S, Smyth A. Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2007;62(6):541-5.
37. UK Cystic Fibrosis Trust Antibiotic Group. Antibiotic treatment for cystic fibrosis. Report of the UK Cystic Fibrosis Trust Antibiotic Group 2009.
38. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, et al.Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348(9028):639-42.
39. David TJ. Intravenous antibiotics at home in children with cystic fibrosis. Journal of the Royal Society of Medicine 1986;82:130-1.
40. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1996;154(5):1229-56.
41. de Groot R, Smith AL. Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance. Clinical Pharmacokinetics 1987;13(4):228-53.
42. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
43. Elphick H, Tan A. Single versus combination intravenous antibiotic therapy for people with cystic fibrosis. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD002007.pub2]
44. Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, et al.Cystic fibrosis pulmonary guidelines. Treatment of pulmonary exacerbations. American Journal of Respiratory and Critical Care Medicine 2009;180(9):802-8. [DOI: 10.1164/rccm.200812-1845PP]
45. Fuchs HJ, Borowitz DS, Christiansen DH. Effect of aerosolised recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. New England Journal of Medicine 1994;331(10):637-42.
46. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
47. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
48. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313(7048):36-9.
49. Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest 2009;135(6):1610-8.
50. Smyth A, Lewis S, Bertenshaw C, Choonara I, McGaw J, Watson A. Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax 2008;63(6):532-5.
51. Smyth AR, Campbell EL. Prescribing practices for intravenous aminoglycosides in UK Cystic Fibrosis clinics: A questionnaire survey. Journal of Cystic Fibrosis 2013 Dec [epub ahead of print]. [DOI: 10.1016/j.jcf.2013.11.007]
52. Spivey JM. The post antibiotic effect. Clinical Pharmacy 1992;11(10):865-75.
53. Tan KH, Hyman-Taylor P, Mulheran M, Knox A, Smyth A. Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centres. Pediatric Pulmonology 2002;33(2):165.
54. Tureen J. Once Daily Intravenous Aminoglycoside Treatment Study. US Cystic Fibrosis Foundation. Planned to be published 2001/2002, terminated.
55. Weiss K, Lapointe JR. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1995;39(11):2411-4.
56. Smyth A, Tan K, Bunn H. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD002009]
57. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD002009.pub2]
58. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD002009.pub3]
59. Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD002009.pub4]